Smoking Not a Risk Factor for Multiple Myeloma

Article

Cigarette smoking is not a risk factor for multiple myeloma, according to the results of a pooled analysis of nine case-control studies.

Smoking does not appear to be a risk factor for multiple myeloma.

Cigarette smoking is not a risk factor for multiple myeloma, according to the results of a pooled analysis of nine case-control studies published in Cancer Epidemiology, Biomarkers & Prevention.

Gabriella Andreotti, MD, of the National Cancer Institute, and colleagues undertook this study in an effort to clarify any relationship between cigarette smoking and multiple myeloma. Previous research had indicated no relationship between the two, but many of these studies may have been underpowered to detect an association, according to the researchers.

For this pooled analysis, Andreotti and colleagues used questionnaire data that included information on cigarette smoking from nine studies that included 2,670 cases of myeloma and 11,913 control cases.

Results showed no increased risk of multiple myeloma among ever smokers (OR = 0.95; 95% CI, 0.87-1.05), current smokers (OR = 0.82; 95% CI, 0.73-0.93), or former smokers (OR = 1.03; 95% CI, 0.92-1.14) compared with never smokers.

“These associations did not change measurably when participants who ceased smoking within 2 years prior to the completion of the questionnaire were re-categorized as current smokers from former smokers,” the researchers wrote. “However, we did find that participants who stopped smoking after age 56 had an almost 40% higher risk of multiple myeloma than those who stopped at age 33 or younger.”

Interestingly, the data showed that women who were ever smokers (OR = 0.83; 95% CI, 0.72-0.96) and current smokers (OR = 0.71; 95% CI, 0.58-0.86) had significantly lower risk for multiple myeloma than did women who were never smokers. The researchers wrote that the reasons for this reduced risk were unclear, but added that the “null exposure-response relationships with smoking frequency, pack-years, and duration of smoking among women argue against smoking being a real protective factor.”

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
Related Content